As GSK Triples Capacity On Flu Drug Relenza, Royalties Trickle In For Aussie Originator Biota
This article was originally published in PharmAsia News
Executive Summary
PERTH, Australia - GlaxoSmithKline's announcement that it will triple its manufacturing capacity of antiviral Relenza is good news for Australian biotech Biota, the developer of the first-in-class neuraminidase inhibitor for which Biota receives 7 percent royalties on global sales